Loading...
•
Mar 31, 2025
Aurinia Q1 2025 Earnings Report
Aurinia reported strong revenue growth and returned to profitability in Q1 2025.
Key Takeaways
Aurinia Pharmaceuticals saw a robust quarter driven by LUPKYNIS sales, leading to a net income of $23.3M and positive operating cash flow.
LUPKYNIS net product sales reached $59.97M, up from $48.07M YoY.
Total revenue increased to $62.47M from $50.3M in Q1 2024.
Net income improved significantly to $23.34M from a net loss of $10.75M in Q1 2024.
Operating cash flow was $1.3M, or $12.4M excluding restructuring costs.
Revenue by Segment
Forward Guidance
Aurinia reaffirmed its 2025 guidance for revenue and product sales, anticipating continued LUPKYNIS momentum.
Positive Outlook
- 2025 total revenue guidance maintained at $250M–$260M.
- Net product sales guidance reiterated at $240M–$250M.
- LUPKYNIS now recommended for first-line therapy in lupus nephritis.
- Initial results for AUR200 expected later this quarter.
- Strong commercial efforts to educate rheumatologists on LUPKYNIS benefits.
Challenges Ahead
- Cash balance declined by $17M from end of 2024.
- Significant share repurchase reduced cash reserves.
- Still dependent on a single commercial product.
- Deferred revenue remained modest despite collaboration.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...